argenx

This study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…

This study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…

This early-stage trial tests a new biologic drug called ARGX-119 in 16 adults with a rare genetic muscle weakness condition called DOK7-congenital myasthenic syndrome (CMS). The study aims to see if the drug is safe and how the body processes it. Participants will receive either …

This study tests a drug called efgartigimod for adults with ocular myasthenia gravis, a condition that causes eye muscle weakness like droopy eyelids or double vision. About 141 people will receive either the drug or a placebo for 7 weeks, then everyone gets the drug for up to 2 …

This study tests a drug called efgartigimod, given as a shot under the skin, for people who have antibody-mediated rejection after a kidney transplant. The trial includes 30 adults who received a kidney at least 6 months ago and have signs of rejection. Participants will receive …

This study tests if a new drug, empasiprubart, works as well as standard IVIg treatment for adults with multifocal motor neuropathy (MMN), a condition that causes muscle weakness. About 154 people who have responded to IVIg in the past will be randomly assigned to receive either …

This study looks at the long-term safety of efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. The 12 participants are kids who already took part in earlier studies of this drug. They will continue to receive efgartigimod either th…

This phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…

This study tests a drug called ARGX-117 in people who get a kidney from a deceased donor and are at risk for delayed graft function (when the kidney takes time to start working). About 103 participants will receive either the drug or a placebo by IV. The goal is to see if the dru…

This study is a long-term follow-up for people with multifocal motor neuropathy, a rare condition that causes muscle weakness. It tests the safety and effectiveness of a drug called ARGX-117, given intravenously. The trial includes 51 adults who previously took part in an earlier…

This study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain safe platele…

This study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…

This study follows about 413 adults with multifocal motor neuropathy (MMN) over time to learn how the disease progresses and affects daily life. Researchers will collect information on symptoms, quality of life, and healthcare use during regular doctor visits. No experimental tre…